Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo tratamiento de la enfermedad de Alzheimer y trastornos relacionados. Concepto para terapia génica somática

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20151119001
Publicado:
27/11/2015
Caducidad:
27/11/2016
Resumen:
Una universidad alemana con experiencia en biología y biotecnología ha desarrollado un enfoque terapéutico que consiste en un vector que codifica un gen del inhibidor CDK4/CDK6 de la familia INk4 y un gen que codifica la proteína transactivadora. Este tratamiento puede prevenir la muerte celular o retrasar el avance. También puede aplicarse a otros trastornos neurodegenerativos y no neuronales con activación del ciclo celular no programada, como cáncer o aterosclerosis. La universidad busca empresas para desarrollar aplicaciones de terapia de genes y realizar las pruebas clínicas dentro de un acuerdo de joint venture.

Details

Tittle:
Innovative treatment of Alzheimer disease and related disorders - Concept for a somatic gene therapy
Summary:
An university from Germany in Saxony developed a therapeutic approach that provides a vector which encodes a gene of the CDK4/CDK6 inhibitor of the INK4 family and a gene encoding a transactivator protein. This can prevent cell death or slow down progression. The university is looking for companies to develop gene therapeutic applications and for clinical testing as part of a Joint Venture or license agreement.
Description:
A German university with focus on biology and biotechnology developed a therapeutic approach that provides a vector which encodes a gene of the CDK4/CDK6 inhibitor of the INK4 family and a gene encoding a transactivator protein.
This vector can be transferred into cells where it will exert its protective function to prevent cell death or to slow down progression of cell death by affecting the cell cycle regulation of targeted cells.
The existing risks with gene therapy and specific challenges for gene therapy posed by the central nervous system will be met through viral or non-viral vectors for safe gene transfer, cell type specific recognition systems, cell-type specific expression system and controlled delivery by convection-enhanced delivery.
The modular character of the gene therapeutic tools allows to adapt the above concept in alternative specifications for the treatment of a wide variety of other neurological disorders where unscheduled cell-cycle re-entry of cells is of critical importance such as Parkinsons´s disease, stroke, amyotrophic lateral sclerosis or proliferative vitreoretinopathy.
The therapeutic applications could be used to prevent neurodegenerative disorders or at least to slow down their progression with therapeutic efficacy.

The university is looking for industrial partners for Joint Venture or license agreements. Main tasks are the development of gene therapeutic applications and the clinical testing of the offered therapeutic approach for Alzheimer desease.
Advantages and Innovations:
·Therapeutic concept of neuroprotection to slow down or even prevent cell death by neuron-specific targeting of the cell cycle
·Neuroprotective effects had been proven on in vivo models of its chemic cell death and excitotoxicity mimicking the effects of Aß (see picture).
·High therapeutic efficacy and minimal or no side-effects based targeted gene transfer in combination with neuron-specific promoters and regulable gene silencer elements
·Anticipation to bring these therapeutic tools in a joined effort to a first clinical application within a framework of five years

AD or stroke will be in the direct focus of the first therapeutic application.
The Approach will also be applicable to other neurodegenerative disorders and non-neuronal disorders with unscheduled cell-cycle activation, such as cancer or atherosclerosis.
Stage of Development:
Prototype available for demonstration
IPs:
Secret know-how

Partner sought

Type and Role of Partner Sought:
Partners sought from Industry to develop gene therapeutic applications and for clinical testing of Alzheimer desease.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001014 Neurología, investigación cerebral
06001013 Tecnología médica / ingeniería biomédica
06001009 Terapia genética - ADN